JGC
CLVS

J. Goldman & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

J. Goldman & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25,700
Closed -$1.64M – 439
2017
Q1 		$1.64M Buy
+25,700
New +$1.56M 0.08% 219
2016
Q4 		– Sell
-28,300
Closed -$1.02M – 418
2016
Q3 		$1.02M Sell
28,300
-307,900
-92% -$6.61M 0.06% 237
2016
Q2 		$4.61M Buy
+336,200
New +$4.91M 0.24% 106

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PointState Capital
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

J. Goldman & Co's CLVS Position: Q2 2017 in Review

J. Goldman & Co sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 25,700 shares — an estimated $1.64M sold.

J. Goldman & Co first reported a position in CLVS in Q2 2016 and held it in 3 quarters. The position peaked at $4.61M in Q2 2016. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

  • J. Goldman & Co reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
  • J. Goldman & Co sold 25,700 Clovis Oncology, Inc. shares in Q2 2017, an estimated $1.64M.
  • J. Goldman & Co first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 3 quarters.
  • J. Goldman & Co's Clovis Oncology, Inc. position peaked at $4.61M in Q2 2016.
  • 271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on J. Goldman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.